Immunotherapy of B-cell malignancies using anti-CD22 antibodies

Details Immunotherapy of B-cell malignancies using anti-CD22 antibodies Immunotherapy of B-cell malignancies using anti-CD22 antibodies

2002-12-09

2010-11-23

Harris, Alana M (Department: 1643)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S130100, C424S130100, C424S133100, C424S134100, C424S135100, C424S136100, C424S138100, C424S144100, C424S152100, C424S154100, C424S155100, C424S156100, C424S174100, C424S178100, C424S181100, C424S183100, C530S350000, C530S386000, C530S387100, C530S387300, C530S387700, C530S388100, C530S388150, C530S388200

Reexamination Certificate

active

07837995

ABSTRACT:
B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 or CD19 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 and/or anti-CD19 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.

REFERENCES:
patent: 4036945 (1977-07-01), Haber
patent: 4331647 (1982-05-01), Goldenberg
patent: 4624846 (1986-11-01), Goldenberg
patent: 4946778 (1990-08-01), Ladner
patent: 5057313 (1991-10-01), Shih et al.
patent: 5120525 (1992-06-01), Goldenberg
patent: 5443953 (1995-08-01), Hansen et al.
patent: 5484892 (1996-01-01), Tedder et al.
patent: 5686072 (1997-11-01), Uhr et al.
patent: 5789554 (1998-08-01), Leung et al.
patent: 6090365 (2000-07-01), Kaminski
patent: 6183744 (2001-02-01), Goldenberg
patent: 6306393 (2001-10-01), Goldenberg
patent: 6846476 (2005-01-01), White
patent: 510 949 (1992-04-01), None
patent: 0510949 (1992-10-01), None
patent: WO 91/11465 (1991-08-01), None
patent: WO 95/09917 (1995-04-01), None
patent: WO 96/04925 (1996-02-01), None
patent: WO 98/42378 (1998-01-01), None
patent: WO 99/02567 (1999-01-01), None
Rudikoff et al. Single amino acid substitution altering antigen-binding specificity. Proc. Natl. Acad. Sci. USA 79: 1979-1983, Mar. 1982.
Maloney et al. Phase I Clinical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Patients with Recurrent B-Cell Lymphoma, Blood 84(8): 2457-2466, Oct. 15, 1994.
Webster's II New Riverside University Dictionary, p. 307, Houghton Mifflin Company, Boston, MA, 1984.
Adang et al.,Plant Molec. Biol., 21:1131 (1993).
Ausubel et al. (eds.),Current Protocols in Molecular Biology, pp. 8.2.8-8.2.13 (1990).
Ausubel et al. (eds.),Short Protocols in Molecular Biology, 3rd Ed., pp. 8-8 to 8-9 (John Wiley & Sons, Inc., 1995).
Baines et al., “Purification of Imunoglobulin G (IgG)”,Methods in Molecular Biology, vol. 10, pp. 79-104, The Humana Press, Inc. (1992).
Bambot et al.,PCR Methods and Applications, 2:266 (1993).
Batra et al.,Proc. Nat'l Acad. Sci. USA, 89:5867 (1992).
Baum et al.,Cancer, 73 (Suppl. 3):896 (1994).
Becker et al.,Proc. Nat'l Acad. Sci. USA, 93:7826 (1996).
Bird et al.,Science, 242:423 (1988).
Boleti et al.,Ann. Oncol., 6:945 (1995).
Brinkmann et al.,Proc. Nat'l Acad. Sci USA, 88:8616 (1991).
Carter et al., Proc. Nat'l Acad. Sci. USA, 89:4285 (1992).
Chase, “Medical Applications of Radioisotopes”,Remington's Pharmaceutical Sciences, 18th Ed., Gennaro et al. (eds.), pp. 624-652, Mack Publishing Co., (1990).
Chaudhary et al.,Nature, 339:394 (1989).
Coligan et al.,Current Protocols in Immunology, vol. I, pp. 2.5.1-2.6.7, pp. 2.7.1-2.7.12; pp. 2.9.1-2.9.3, pp. 2.8.1-2.8.10; 2.10-2.10-4, John Wiley & Sons (1991).
Courtenay-Luck et al., “Genetic Manipulation of Monoclonal Antibodies”,Monoclonal Antibodies: Production, Engineering and Clinical Application, Ritter et al. (eds.), pp. 166-179, Cambridge University Press (1995).
Deonarain et al.,Tumor Targeting, 1:177 (1995).
Devesa et al.,J. Nat'l Cancer Inst., 79:701 (1987).
Dillman,J. Clin. Oncol., 12(7):1497 (1994).
Dillon et al., “Use of the Polymerase Chain Reaction for the Rapid Construction of Synthetic Genes”,Methods in Molecular Biology, vol. 15: PCR Protocols: Current Methods and Applications (White, ed.), pp. 263-268, Humana Press, Inc. (1993).
Dohlsten et al.,Proc. Nat'l Acad. Sci. USA, 91:8945 (1994).
Edelman et al.,Methods in Enzymology, vol. 1, p. 422, Academic Press (1967).
Fominaya et al.,J. Biol. Chem., 271:10560 (1996).
Friedman et al.,J. Immunol., 150:3054 (1993).
Foon et al.,Annals Int. Medicine, 113:525 (1990).
Freedman,Hematol. Oncol. Clin. North Am., 4:405 (1990).
Freedman et al., “Non-Hodgkin's Lymphomas”,Cancer Medicine, vol. 2, 3rd Ed., Holland et al. (eds.), pp. 2028-2068, Lea & Febiger (1993).
Gennaro et al.,Remington's Pharmaceutical Sciences, 19th Ed., Mack Publishing Co. (1995).
Ghetie et al.,Cancer Res., 48:2610 (1988).
Goldenberg et al.,J. Clin. Oncol., 9:548 (1991).
Goldenberg et al.,A Cancer J. for Clinicians, 44:43 (1994).
Goodman et al.,Leukemia and Lymphoma, 22:1 (1996).
Goodman and Gilman's The Pharmacological Basis of Therapeutics, 7th Ed., MacMillan Publishing Co. (1985).
Grossbard et al.,Blood, 80(4):863 (1992).
Hank et al.,Clin. Cancer Res., 2:1951 (1996).
Hasan et al.,Prog. Clin. Biol. Res., 288:471 (1989).
Hekman et al.,Cancer Immunol. Immunother., 32:364 (1991).
Hu et al.,Cancer Res., 56:4998 (1996).
Inbar et al.,Proc. Nat'l Acad. Sci. USA, 69:2659 (1972).
Jones et al.,Nature, 321:522 (1986).
Jori et al. (eds.),Photodynamic Therapy of Tumors and Other Diseases, Libreria Progetto (1985).
Kohler et al.,Nature, 256:495 (1975).
Klegerman et al., “Lymphokines and Monokines”,Biotechnology and Pharmacy, Pessuto et al. (eds.), pp. 53-70 (Chapman & Hall, 1993).
Kreitman et al.,Leukemia, 7:553 (1993).
Kuan et al.,Biochemistry, 35:2872 (1996).
Larrick et al.,Methods: A Companion to Methods in Enzymology, 2:106 (1991).
Leung et al.,Hybridoma, 13:469 (1994).
Leung et al.,Mol. Immunol., 32:1413 (1995).
Leung et al.,J. Immunol., 154:5919 (1995).
Lienard et al.,J. Clin. Oncol., 10:52 (1992).
Linardou et al.,Cell Biophys., 24-25:243 (1994).
Lonberg et al.,Nature, 368:856 (1994).
Longo,Curr. Opin. Oncol., 8:353 (1996).
Losman et al.,Int. J. Cancer, 46:310 (1990).
Lundberg,J. Pharm. Sci., 83:72 (1993).
Lundberg,Int. J. Pharm., 134:119 (1996).
Mew et al.,J. Immunol., 130:1473 (1983).
Mew et al.,Cancer Res., 45:4380 (1985).
Mills et al.,Proc. Am. Assoc. Cancer Res., 34:479 (1993) (abstract No. 2857).
Mole et al., “Epitope Mapping”,Methods in Molecular Biology, vol. 10, Immunochemical Protocols, Manson (eds.), pp. 105-116, The Humana Press, Inc. (1992).
Murthy et al,Eur. J. Nucl. Med., 19:394 (1992).
Nadeau et al.,J. Pharmacol. Exp. Ther., 274:78 (1995).
Nicholls et al.,J. Biol. Chem., 268:5302 (1993).
Nicolet et al.,Cancer Gene Ther., 2:161 (1995).
Nisonoff et al.,Arch Biochem. Biophys., 89:230 (1960).
Orlandi et al.,Proc. Natl. Acad Sci. USA, 86: 3833 (1989).
Oseroff et al.,Proc. Natl. Acad. Sci. USA, 83:8744 (1986).
Oseroff et al.,Photochem. Photobiol., 46:83 (1987).
Pack et al.,Bio/Technology, 11:1271 (1993).
Pastan et al,Cell, 47:641 (1986).
Patti et al.,Eur. J. Haematol., 51:18 (1993).
Pawlak-Byczkowska et al.,Cancer Res., 49:4568 (1989).
Pèlegrin et al.,Cancer, 67:2529 (1991).
Porter et al.,Biochem. J., 73:119 (1959).
Press et al.,N. Engl. J. Med., 329:1219 (1993).
Press et al.,Lancet, 346:336 (1995).
Price, “Production and Characterization of Synthetic Peptide-Derived Antibodies”,Monoclonal Antibodies: Production, Engineering and Clinical Application, Ritter et al. (eds.), pp. 60-84, Cambridge University Press (1995).
Riechmann et al.,Nature, 332:323 (1988).
Saltzman et al.,Biophys. J., 55:163 (1989).
Sandhu,Crit. Rev. Biotech., 12:437 (1992).
Schmidt et al.,Int. J. Can., 65:538 (1996).
Schwartz-Albiez et al., “The Carbohydrate Moiety of the CD22 Antigen Can be Modulated by Inhibitors of the Glycosylation Pathway”,Leukocyte Typing IV: White Cell Differentiation Antigens, Knapp et al. (eds.), p. 65, Oxford University Press (1898).
Sherwood et al.,Bio/Technology, 10:1446 (1992).
Shih et al.,Int. J. Cancer, 41:832-839 (1988).
Shih et al.,Int. J. Cancer, 46:1101-1106 (1990).
Shih et al.,Int. J. Cancer, 56:538 (1994).
Singer et al.,J. Immunol., 150:2844 (1993).
Stein et al.,Antibody lmmunoconj.

Affiliated with

Also associated with

Rating

Immunotherapy of B-cell malignancies using anti-CD22 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunotherapy of B-cell malignancies using anti-CD22 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunotherapy of B-cell malignancies using anti-CD22 antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4246998